Bristol Myers Squibb Raises Full-Year Forecast on Eliquis Sales Surge
Bristol Myers Squibb raised its full-year revenue forecast on Thursday after second-quarter results exceeded expectations. The pharmaceutical company's performance was driven by strong sales of the blood thinner Eliquis, as well as newer drugs including heart medication Camzyos and anemia treatment Reblozyl.
Key facts
- Bristol Myers Squibb raised its full-year revenue forecast on Thursday.
- Second-quarter results were better than expected.
- Sales of blood thinner Eliquis surged past expectations.
- Newer drugs Camzyos (heart) and Reblozyl (anemia) also contributed to growth.
Entities
Institutions
- Bristol Myers Squibb
Sources
- Quartz —